The OASIS study: Therapeutic management of acromegaly in standard clinical practice. Assessment of the efficacy of various treatment strategies;Estudio OASIS: Manejo terapéutico de la acromegalia en un escenario de práctica clínica habitual. Evaluación de la eficacia de las diversas estrategias de tratamiento aplicadas

Endocrinologia y Nutricion

Volumn 58, Issue 9, 2011, Pages 478-486

  Luque Ramírez, Manuel ^a   Carreño, ágata ^b   álvarez Escolá, Cristina ^c   del Pozo Picó, Carlos ^d   Varela da Costa, César ^e   Fajardo Montañana, Carmen ^f   Gilabert, Montserrat ^g   Webb, Susan ^h   Albero R , ⁱ   Acha J , ⁱ   Ballesteros M , ^j   Bernal C , ^k   Blanco C , ^l   Boronat M , ^m   Catala M ⁿ   Diez A ^o   Donnay S , ^p   Fernandez P ^q   Ferrer J C , ^r   Garcia A ^s   Garcia H ^t   Gaztambide S , ^u   Lopez J F ^v   Lopez P ^w   de Luis D , ^x   Martinez P ^y   Montreal M , ⁱ   Moreno A , ^y   Pardo C , ^z   Pavon I ^aa   Pazos F , ^ab   Perez J ^ac   Pinedo R , ^ad   Rodriguez P ^ae   Salinas I , ^af   Sanabria C , ^ag   Sillero A , ^ah   Soto A , ^ai   Tarroba C , ^x   Villabona C , ^aj   more..

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b IQVIA   (United States)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d HOSPITAL MÚTUA DE TERRASSA   (Spain)

^e HOSPITAL RAMÓN Y CAJAL   (Spain)

^f HOSPITAL DE LA RIBERA   (Spain)

^g Novartis   (Spain)

^h INSTITUTO DE SALUD CARLOS III   (Spain)

ⁱ HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^j HOSPITAL DE LEÓN   (Spain)

^k HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^l HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^m HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

ⁿ HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^o HOSPITAL EL BIERZO   (Spain)

^p HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^q HOSPITAL MONTECELO   (Spain)

^r HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^s HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^t HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^u HOSPITAL DE CRUCES   (Spain)

^v HOSPITAL RAFAEL MÉNDEZ   (Spain)

^w HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^x HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^y Servicio Andaluz de Salud   (Spain)

^z HOSPITAL VIRGEN DE LOS LIRIOS   (Spain)

^aa HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^ab HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^ac HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^ad HOSPITAL GENERAL DE ELDA   (Spain)

^ae HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^af HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^ag HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^ah Hospital de Merida   (Spain)

^ai HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^aj HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

more..

Author keywords

Acromegaly; Clinical practice; Neurosurgery; Somatostatin analogs; Treatment efficacy

Indexed keywords

SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADENOMA; ADULT; ARTICLE; CLINICAL PRACTICE; DISEASE CONTROL; ENDOCRINE SURGERY; FOLLOW UP; HUMAN; HYPOPHYSIS; HYPOPHYSIS ADENOMA; LONGITUDINAL STUDY; MACROADENOMA; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR VOLUME;

ACROMEGALY; ADENOMA; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 82755177866     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/j.endonu.2011.09.002     Document Type: Article

References (35)

1. Mestrón A., Webb S.M., Astorga R., Benito P., Catalá M., Gaztambide S., et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Español de Acromegalia, REA). Eur J Endocrinol 2004, 151:439-446.
2. Holdaway I.M., Rajasoorya R.C., Gamble G.D. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004, 89:667-674.
3. Holdaway I.M. Excess mortality in acromegaly. Horm Res 2007, 68:166-172.
4. Dekkers O.M., Biermasz N.R., Pereira A.M., Romijn J.A., Vandenbroucke J.P. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 2008, 93:61-67.
5. Rajasoorya C., Holdaway I.M., Wrightson P., Scott D.J., Ibbertson H.K. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994, 41:95-102.
6. Colao A., Ferone D., Marzullo P., Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004, 25:102-152.
7. Biermasz N.R., Dekker F.W., Pereira A.M., van Thiel S.W., Schutte P.J., van Dulken H., et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 2004, 89:2789-2796.
8. Giustina A., Chanson P., Bronstein M.D., Klibanski A., Lamberts S., Casanueva F.F., et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010, 95:3141-3148.
9. Melmed S., Colao A., Barkan A., Molitch M., Grossman A.B., Kleinberg D., et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009, 94:1509-1517.
10. Freda P.U., Wardlaw S.L., Post K.D. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg 1998, 89:353-358.
11. Swearingen B., Barker FGn, Katznelson L., Biller B.M., Grinspoon S., Klibanski A., et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998, 83:3419-3426.
12. Nomikos P., Buchfelder M., Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol 2005, 152:379-387.
13. Freda P.U. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002, 87:3013-3018.
14. Colao A., Pivonello R., Auriemma R.S., Briganti F., Galdiero M., Tortora F., et al. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 2006, 91:2112-2118.
15. Barker 2nd F.G., Klibanski A., Swearingen B. Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 2003, 88:4709-4719.
16. Freda P.U., Katznelson L., van der Lely A.J., Reyes C.M., Zhao S., Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005, 90:4465-4473.
17. Giustina A., Barkan A., Casanueva F.F., Cavagnini F., Frohman L., Ho K., et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000, 85:526-529.
18. Sesmilo G., Webb S.M. Twelve years of the Spanish acromegaly registry: a historical view of acromegaly management in Spain. Endocrinol Nutr 2010, 57:39-42.
19. Bex M., Abs R., T'Sjoen G., Mockel J., Velkeniers B., Muermans K., et al. AcroBel--the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects. Eur J Endocrinol 2007, 157:399-409.
20. Petersenn S., Buchfelder M., Reincke M., Strasburger C.M., Franz H., Lohmann R., et al. Results of surgical and somatostatin analog therapies and their combination in acromegaly: a retrospective analysis of the German Acromegaly Register. Eur J Endocrinol 2008, 159:525-532.
21. Bates P.R., Carson M.N., Trainer P.J., Wass J.A. Wide variation in surgical outcomes for acromegaly in the UK. Clin Endocrinol (Oxf) 2008, 68:136-142.
22. Ahmed S., Elsheikh M., Stratton I.M., Page R.C., Adams C.B., Wass J.A. Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf) 1999, 50:561-567.
23. Lissett C.A., Peacey S.R., Laing I., Tetlow L., Davis J.R., Shalet S.M. The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Clin Endocrinol (Oxf) 1998, 49:653-657.
24. Página web de la Sociedad Española de Neurocirugía: última visita: 3 Mayo 2011. http://www.senec.es/.
25. Plockinger U., Quabbe H.J. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study. Acta Neurochir (Wien) 2005, 147:485-493. discussion 93.
26. Carlsen S.M., Lund-Johansen M., Schreiner T., Aanderud S., Johannesen O., Svartberg J., et al. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab 2008, 93:2984-2990.
27. Colao A., Attanasio R., Pivonello R., Cappabianca P., Cavallo L.M., Lasio G., et al. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2006, 91:85-92.
28. Karavitaki N., Turner H.E., Adams C.B., Cudlip S., Byrne J.V., Fazal-Sanderson V., et al. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clin Endocrinol (Oxf) 2008, 68:970-975.
29. Cozzi R., Montini M., Attanasio R., Albizzi M., Lasio G., Lodrini S., et al. Primary treatment of acromegaly with octreotide LAR: a long term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006, 91:1397-1403.
30. Luque-Ramirez M., Portoles G.R., Varela C., Albero R., Halperin I., Moreiro J., et al. The efficacy of octreotide LAR as firstline therapy for patients with newly diagnosed acromegaly is independent of tumor extension: predictive factors of tumor and biochemical response. Horm Metab Res 2009, 42:38-44.
31. Knutzen R., Ezzat S. The cost of medical care for the acromegalic patient. Neuroendocrinology 2006, 83:139-144.
32. Luque-Ramírez M., Páramo C., Varela da Costa C., García-Mayor R.V. Cost of management of invasive growth hormone-secreting macroadenoma. J Endocrinol Invest 2007, 30:541-545.
33. Trainer P.J., Drake W.M., Katznelson L., Freda P.U., Herman-Bonert V., van der Lely A.J., et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000, 342:1171-1177.
34. Marazuela M., Lucas T., Álvarez-Escolá C., Puig-Domingo M., de la Torre N.G., de Miguel-Novoa P., et al. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy. Eur J Endocrinol 2009, 160:535-542.
35. Bernabeu I., Álvarez-Escolá C., Quinteiro C., Lucas T., Puig-Domingo M., Luque-Ramírez M., et al. The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly. J Clin Endocrinol Metab 2010, 95:222-229.